Barclays Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $20.00

Sarepta Therapeutics (NASDAQ:SRPT) had its target price reduced by Barclays from $22.00 to $20.00 in a report issued on Wednesday morning,Benzinga reports. They currently have an equal weight rating on the biotechnology company’s stock.

SRPT has been the topic of several other reports. HC Wainwright reiterated a “sell” rating on shares of Sarepta Therapeutics in a research note on Monday, August 25th. The Goldman Sachs Group boosted their price target on Sarepta Therapeutics to $19.00 and gave the company a “neutral” rating in a research note on Thursday, August 7th. BMO Capital Markets upgraded Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and set a $50.00 price target on the stock in a research report on Monday, September 22nd. UBS Group reaffirmed a “neutral” rating on shares of Sarepta Therapeutics in a report on Monday, July 21st. Finally, Needham & Company LLC reaffirmed an “underperform” rating on shares of Sarepta Therapeutics in a report on Monday, July 28th. Eight equities research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and six have issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $33.75.

Sarepta Therapeutics Trading Down 0.1%

Shares of SRPT stock opened at $17.63 on Wednesday. The firm has a fifty day moving average of $20.30 and a 200-day moving average of $25.91. The stock has a market cap of $1.72 billion, a price-to-earnings ratio of -20.26 and a beta of 0.52. Sarepta Therapeutics has a 52-week low of $10.41 and a 52-week high of $138.81. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.81 and a current ratio of 2.89.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Monday, November 3rd. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.15). Sarepta Therapeutics had a negative net margin of 2.34% and a negative return on equity of 1.03%. The business had revenue of $399.36 million during the quarter, compared to the consensus estimate of $331.51 million. During the same period in the previous year, the firm earned $0.62 EPS. The business’s revenue was down 14.5% compared to the same quarter last year. On average, equities research analysts forecast that Sarepta Therapeutics will post 2.67 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in SRPT. Ancora Advisors LLC increased its position in shares of Sarepta Therapeutics by 150.0% during the 1st quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 300 shares during the last quarter. Pandora Wealth Inc. bought a new stake in shares of Sarepta Therapeutics during the first quarter worth approximately $45,000. Brooklyn Investment Group grew its stake in shares of Sarepta Therapeutics by 450.4% in the first quarter. Brooklyn Investment Group now owns 721 shares of the biotechnology company’s stock valued at $46,000 after acquiring an additional 590 shares in the last quarter. Banque Transatlantique SA acquired a new stake in Sarepta Therapeutics during the first quarter worth approximately $44,000. Finally, Hurley Capital LLC raised its stake in Sarepta Therapeutics by 139.2% in the first quarter. Hurley Capital LLC now owns 1,435 shares of the biotechnology company’s stock valued at $92,000 after purchasing an additional 835 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.